NWBO will be just fine. Their Sawston Manufacturing Facility in the UK is up and running and the pieces are surely falling into place. Now you have Dr. Linda Laui from UCLA and one of the top Neurosurgeons in the World, giving a presentation on DCvax at SNO in Nov touting significant OS in r-GBM and n-GBM. Part of the abstract is already available to view. She is also the PI on several combo trials with DCVax and checkpoint inhibitors......the early data is very,very promising. One of which is DCvax/Keytruda. When you report SOC changing TLD for r & n GBM, the money will eventually come to you. Do you think the likes of Merck is going to let NW Bio go at this alone as with Keytruda, Mercks blockbuster drug expiring soon? I certainly don't think so. NW Bio is at the finish line. With manufacturing already in place and the UK MHRA basically spelling out approval fo DCVax, revenue is very,very near and will quell any issues concerning cash. The fact that NW Bio, against all odds, has come this far is nothing short of a freaking miracle. The Stupp Protocol for GBM is about to be changed to the Liau Protocol within the next year.
-Fireman
News 
Market Data 
Discover 
